Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
Phase 3
Recruiting
- Conditions
- Assessing the immunological responses and adverse reactions elicited by the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccinationCOVID-19SAR-CoV-2 second booster doseheterologous vaccinationBNT162b2CoronaVachealthcare workers
- Registration Number
- TCTR20221112001
- Lead Sponsor
- The National Science Research and Innovation Fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 340
Inclusion Criteria
20 years old or older who never had prior clinical symptoms of SARS-CoV-2 infection.
Exclusion Criteria
immunocompromised persons, receiving immunosuppressive drugs, receiving blood products and pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The IgG against the SARS-CoV-2-spike protein 4 and 24 weeks after the second booster dose of BNT162b2. fluoroenzymeimmunoassay
- Secondary Outcome Measures
Name Time Method Adverse reactions at the first 3 days, 4 weeks and 24 weeks after the second booster dose of BNT162b2. Case record form